A research group led by hemato-oncologist Philipp Staber, from the Medical University of Vienna’s Division of Hematology and Hemostaseology, and biochemist Stefan Kubicek, from the Research Center for Molecular Medicine, found that venetoclax (BCL-2 inhibitor) is useful in T-PLL. The gene discussed is BCL2; the disease is T-cell prolymphocytic leukemia.